Protalix BioTherapeutics (NYSE: PLX) announced that the first Gaucher patient has been enrolled in the Company's phase IIa clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE